WO2014055766A1 - Ballon intra-gastrique servant à traiter l'obésité - Google Patents

Ballon intra-gastrique servant à traiter l'obésité Download PDF

Info

Publication number
WO2014055766A1
WO2014055766A1 PCT/US2013/063276 US2013063276W WO2014055766A1 WO 2014055766 A1 WO2014055766 A1 WO 2014055766A1 US 2013063276 W US2013063276 W US 2013063276W WO 2014055766 A1 WO2014055766 A1 WO 2014055766A1
Authority
WO
WIPO (PCT)
Prior art keywords
balloon
stomach
intragastric
intragastric balloon
region
Prior art date
Application number
PCT/US2013/063276
Other languages
English (en)
Inventor
Justin J. SCHWAB
Zachary P. Dominguez
Joseph S. Raven
Mitchell H. Babkes
Christopher S. Mudd
Tiago Bertolote
Original Assignee
Apollo Endosurgery, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/645,026 external-priority patent/US8870966B2/en
Application filed by Apollo Endosurgery, Inc. filed Critical Apollo Endosurgery, Inc.
Priority to US14/433,752 priority Critical patent/US9795498B2/en
Publication of WO2014055766A1 publication Critical patent/WO2014055766A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/0003—Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0013—Implantable devices or invasive measures
    • A61F5/003—Implantable devices or invasive measures inflatable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
    • A61F5/0003—Apparatus for the treatment of obesity; Anti-eating devices
    • A61F5/0013—Implantable devices or invasive measures
    • A61F5/0036—Intragastrical devices

Definitions

  • the present invention is an intragastric device and uses thereof for treating obesity, weight loss and/or obesity-related diseases and, more specifically, to transorally (as by endoscopy) delivered intragastric devices designed to occupy space within a stomach and/or stimulate the stomach wall and react to changing conditions within the stomach.
  • Obesity is caused by a wide range of factors including genetics, metabolic disorders, physical and psychological issues, lifestyle, and poor nutrition. Millions of obese and overweight individuals first turn to diet, fitness and medication to lose weight; however, these efforts alone are often not enough to keep weight at a level that is optimal for good health.
  • Surgery is another increasingly viable alternative for those with a Body Mass Index (BMI) of greater than 40. In fact, the number of bariatric surgeries in the United States was estimated to be about 400,000 in 2010.
  • Examples of surgical methods and devices used to treat obesity include the LAP- BAND® (Allergan Medical of Irvine, CA) gastric band and the LAP-BAND AP® (Allergan). However, surgery might not be an option for every obese individual; for certain patients, non-surgical therapies or minimal-surgery options are more effective or appropriate.
  • the BIB System comprises a silicone elastomer intragastric balloon that is inserted into the stomach and filled with fluid. Conventionally, the balloons are placed in the stomach in an empty or deflated state and thereafter filled (fully or partially) with a suitable fluid. The balloon occupies space in the stomach, thereby leaving less room available for food and creating a feeling of satiety for the patient. Placement of the intragastric balloon is non-surgical, trans-oral, usually requiring no more than 20-30 minutes.
  • the procedure is performed gastroscopically in an outpatient setting, typically using local anesthesia and sedation. Placement of such balloons is temporary, and such balloons are typically removed after about six months. Removing the balloon requires deflation by puncturing with a gastroscopic instrument, and either aspirating the contents of the balloon and removing it, or allowing the fluid to pass into the patient's stomach. Clinical results with these devices show that for many obese patients, the intragastric balloons significantly help to control appetite and accomplish weight loss.
  • a transorally inserted intragastric device of the present invention can be used to treat obesity and/or for weight control.
  • the device can do this by causing a feeling or a sensation of satiety in the patient on several basis, for example by contacting the inside or a portion of the inside of the stomach wall of the patient.
  • the transoral intragastric device allows for easy and quick placement and removal. Surgery is usually not required or is very minimal.
  • the transoral intragastric device can be placed in the patient's stomach through the mouth and the esophagus and then being placed to reside in the stomach.
  • the transoral intragastric device does not require suturing or stapling to the esophageal or stomach wall, and can remain inside the patient's body for a lengthy period of time (e.g., months or years) before removal.
  • Each of the disclosed devices is formed of materials that will resist degradation over a period of at least six months within the stomach.
  • the implantable devices are configured to be compressed into a substantially linear transoral delivery configuration and placed in a patient's stomach transorally without surgery to treat and prevent obesity by applying a pressure to the patient's stomach.
  • a transoral intragastric device can be used to treat obesity or to reduce weight by stimulating the stomach walls of the patient.
  • the intragastric spring device can be a purely mechanical device comprising a flexible body which in response to an input force in one direction, may deform and cause a resultant displacement in an orthogonal direction, thereby exerting a pressure on the inner stomach walls of the patient.
  • a transoral orthogonal intragastric device can include a variable size balloon.
  • the balloon may be configured to occupy volume in the patient's stomach, thereby reducing the amount of space in the patient's stomach.
  • a still further reactive implantable device disclosed herein has an inflatable body with an internal volumetric capacity of between 400-700 ml and being made of a material that permits it to be compressed into a substantially linear transoral delivery configuration and that will resist degradation over a period of at least six months within the stomach.
  • the body has a central inflatable member and at least two outer wings, and a single internal fluid chamber such that fluid may flow between the central inflatable member and the outer wings.
  • the inflatable body is under filled with fluid such that the outer wings are floppy in the absence of compressive stress on the central inflatable member and stiff when compressive stress from the stomach acts on the central inflatable member.
  • the central inflatable member may have a generally spherical shape along an axis. There are preferably two outer wings extending in opposite directions from the generally spherical inflatable member along the axis. In one form, each of the outer wings includes a narrow shaft portion connected to the central inflatable member terminating in bulbous heads.
  • An embodiment of the present invention can be an intragastric balloon configured to be implanted transorally into a patient's stomach to treat obesity.
  • Such an intragastric balloon can comprise an inflatable hollow body, the body having a volume which is substantially the same both before and after inflation of the body with a fluid.
  • the body can be made of a material that permits the body to be compressed into a substantially linear transoral delivery configuration, and that will resist degradation over a period of at least six months within the stomach.
  • the body can have a single internal chamber with one or more interconnected regions, such that the fluid can flow between each region, the inflatable body being under filled with the fluid such that the once inflated the body is not rigid, thereby having the capability to confirm to the shape of a the stomach.
  • the volume can be between about 300 ml and about 700 ml.
  • An embodiment of the intragastric balloon disclosed in the paragraph can have three regions, a proximal region for inducing satiety by exerting a pressure on the stomach, a larger central region for inducing satiety by providing a stomach volume occupying effect, and a smaller distal region for anchoring the balloon within the stomach.
  • the intragastric balloon can also have an increased thickness of the distal region shapes for preventing migration of the balloon out of the distal stomach.
  • the intragastric can also have in the central region a circumferential ring to for help prevent collapse of the balloon.
  • in the proximal region of the balloon there can be a spine for maintaining the shape of the balloon.
  • An detailed embodiment of the present invention can be an intragastric balloon configured to be implanted transorally into a patient's stomach to treat obesity, the intragastric balloon comprising: an inflatable hollow body, the body having a volume between about 300 ml and about 700 mis, which volume is substantially the same both before and after inflation of the body with a fluid, wherein the body is made of a material that permits the body to be compressed into a substantially linear transoral delivery configuration, and that will resist degradation over a period of at least six months within the stomach, wherein the body has a single internal chamber with one or more interconnected regions, such that the fluid can flow between each region, the inflatable body being under filled with the fluid such that the once inflated the body is not rigid, thereby having the capability to confirm to the shape of a the stomach, wherein the body has three regions, a proximal region for inducing satiety by exerting a pressure on the stomach, a larger central region for inducing satiety by providing a stomach volume occupying effect, and
  • Figure 1 illustrates a reactive intragastric implant comprising an under filled inflatable member having outer wings that transition between floppy to stiff configurations.
  • Figures 2A and 2B show the intragastric implant of Figure 1 implanted in the stomach in both relaxed and squeezed states, showing the transition of the outer wings between floppy and stiff configurations.
  • Figure 3A is diagram illustrating on the left hand side of Figure 3A an unfilled known intragastric balloon.
  • the right pointing arrow in Figure 3A represents filling 700 ml of saline into the unfilled intragastric balloon, resulting as shown on the right hand side of Figure 3A in a balloon shell that is stretched and a balloon that is rigid.
  • the upwards pointing arrow in Figure 3A represents the high pressure that is exerted by the 700 ml filled balloon onto the inside wall of a patient's stomach by the so filled intragastric balloon.
  • differential pressure > 0 there is a positive differential pressure in the balloon relative to outside of the balloon
  • Figure 3B is a corresponding diagram illustrating on the left hand side of Figure 3B an unfilled compliant intragastric balloon.
  • the right pointing arrow in Figure 3B represents filling 700 ml of saline into the unfilled intragastric balloon, resulting as shown on the right hand side of Figure 3BA in a balloon shell that is under minimal strain and a balloon that is compliant.
  • the downwards pointing arrow in Figure 3B represents the lower pressure that is exerted by the 700 ml filled compliant balloon, by a differing or amorphous balloon shell shape, onto the inside wall of a patient's stomach by the so filled compliant intragastric balloon.
  • differential pressure is zero or almost zero
  • Figure 4 is an illustrative, perspective view of a saline containing compliant balloon implanted within a patient's stomach, with the proximal (near) stomach wall removed to show the balloon therein.
  • Figure 5 is a perspective view of the mandrel (the work piece or mold) over which a liquid polymer (i.e. silicone) dispersion is placed (as by a serial dipping procedure) and then heat cured so as to create the compliant balloon of Figure 4.
  • a liquid polymer i.e. silicone
  • Figures 6A to 6G are diagramatic illustrations of compliant balloon geometries, alternative to those of Figures 4 and 5, within the scope of the present invention.
  • Figure 7 is an illustrative, perspective view of a further embodiment (kidney shaped), saline containing compliant balloon implanted within a patient's stomach, with the proximal (near) stomach wall removed to show the balloon therein.
  • Figure 8A to 8C are diagramatic illustrations of three further embodiments of compliant balloons within the scope of the present invention.
  • Figure 9A is a diagram of a mandrel useful for making a further embodiment of the present intragastric balloon.
  • Figure 9B is a diagram of another mandrel useful for making a further embodiment of the present intragastric balloon.
  • Figure 9C is a diagram of another mandrel useful for making a further embodiment of the present intragastric balloon.
  • Figure 9D is a diagram of another mandrel useful for making a further embodiment of the present intragastric balloon.
  • Figure 10 is a diagram of an inflated intragastric balloon made using the Figure 9A mandrel.
  • Figure 1 1 is a perspective photograph of an intragastric balloon of the present invention enclosed by a novel delivery sheath.
  • the present invention is based on the discovery that an under filled intragastric balloon can be made to have, once so under filed ("inflated"), a geometry (shape upon inflation) which is flexible or "amorphous", as opposed to having a rigid shape. Unlike the present invention, a rigid upon inflation intragastric balloon does not conform to the shape of the lumen of the stomach into which the balloon is implanted.
  • an intragastric device described herein can be placed inside the patient, transorally and without invasive surgery, without associated patient risks of invasive surgery and without substantial patient discomfort. Patient recovery time can be minimal as no extensive tissue healing is required.
  • the life span of the intragastric devices can be material dependent and is intended for long term survivability within an acidic stomach environment for a least about six months, although it can be one year or longer.
  • FIG. 1 illustrates a reactive intragastric implant 100 comprising an under filled central inflatable member 102 having outer wings 104 that transition between floppy to stiff configurations.
  • the entire implant 100 defines a single fluid chamber therein.
  • the inflatable member 102 is substantially spherical, while the outer wings 104 resemble stems with a narrow proximal shaft 106 terminating in a bulbous head 108.
  • a pair of the outer wings 104 extend from opposite poles of the spherical inflatable member 102, which is believed to facilitate alignment of the implant 100 within the stomach, though more than two such wings distributed more evenly around the inflatable member could be provided.
  • Figure 2A shows the intragastric implant 100 implanted in the stomach in a relaxed state
  • Figure 2B shows the implant 100 in a squeezed state, illustrating the transition of the outer wings 104 between floppy (Figure 2A) and stiff (Figure 2B) configurations.
  • the shape of the central inflatable member 102 in Figure 2B is a representation of the shape as if squeezed by the surrounding stomach walls, however the illustrated stomach is shown in its relaxed configuration. Transition between the relaxed and squeezed state of the implant 100 occurs when the stomach walls squeeze the central inflatable member 102, thus pressurizing the outer wings 104. In other words, fluid is driven from the central member 102 and into the outer wings 104.
  • the entire implant 100 is under filled with a fluid such as saline or air to a degree that the wings 104 are floppy, and a predetermined compressive force causes them to become stiff.
  • a fluid such as saline or air
  • the fully filled volume of the intragastric implant 100 may be between 400-700 ml, though the implant is filled with less than that, thus providing slack for flow into the wings 104.
  • under filling the implant 100 results in lower stresses within the shell wall, which may improve the degradation properties of the material within the stomach's harsh environment.
  • any of the embodiments described herein may utilize materials that improve the efficacy of the implant.
  • a number of elastomeric materials may be used including, but not limited to, rubbers, fluorosilicones, fluoroelastomers, thermoplastic elastomers, or any combinations thereof.
  • the materials are desirably selected so as to increase the durability of the implant and facilitate implantation of at least six months, and preferably more than 1 year.
  • Material selection may also improve the safety of the implant. Some of the materials suggested herein, for example, may allow for a thinner wall thickness and have a lower coefficient of friction than the implant.
  • the implantable devices described herein will be subjected to clinical testing in humans.
  • the devices are intended to treat obesity, which is variously defined by different medical authorities.
  • overweight and “obese” are labels for ranges of weight that are greater than what is generally considered healthy for a given height.
  • the terms also identify ranges of weight that have been shown to increase the likelihood of certain diseases and other health problems.
  • An embodiment of the present invention is an intragastric balloon with a tolerance greater than that of the intragastric balloon shown in Figures, 1 , 2 and 3A. Greater tolerance can be achieved by having a larger allowable amount of variation of a specified quantity, such as in the volume and/or in the shape, of the intragastric balloon of the present invention. Such a greater tolerance intragastric balloon can also be referred to as a more compliant intragastric balloon. A more compliant intragastric balloon can provide many advantages for the treatment of obesity.
  • known intragastric balloons require the device be filled with from 400 ml to 900 ml of a fluid (typically saline or air) resulting once so filled in an intragastric balloon with a rigid, spherical implant geometry (as in Figure 3A).
  • a fluid typically saline or air
  • Such a geometry can be responsible for one or more of the known post-op (that is after transoral placement [implantation] of the intragastric device into the lumen of the stomach of a patient) adverse effects which can include nausea, intolerance (demanded removal of the device), abdominal pain, vomiting, reflux, and gastric perforation.
  • known intragastric devices undergo significant strain, and provide a relatively rigid fluid filled (inflated) balloon.
  • An intragastric balloon with increased tolerance (compliance) according to the present invention can provide superior gastric volume occupying benefits as compared to a known intragastric balloon, such as the ORBERATM bariatric intragastric balloon, (available from Allergan UK, Marlow, England), as well as reduced adverse events in the period following device implantation.
  • ORBERATM is a saline filled silicone balloon that is placed in the stomach of a patient, filled with 400-700 ml of saline, and then left in the stomach for up to six months to provide a feeling of fullness, reduced appetite and weight loss.
  • An embodiment of the present invention is an intragastric balloon with increased tolerance (a "compliant balloon” therefore) with a shell (a volume holding reservoir), and a valve for inflation. Both parts can be made of silicone or other suitable material and can be implanted and explanted transorally, through the esophagus, and into/out of the stomach during a minimally invasive gastroendoscopic procedure.
  • the compliant balloon of the present invention upon inflation has an amorphous or variable (non-rigid) geometry due to the relationship between the volume of the shell and volume of fluid that is placed into (used to fill) the shell. Additionally, the compliant balloon has a relatively larger and more relaxed silicone shell (as compared to a device such as ORBERATM) thereby making the shell strain and rigidity comparably less than known intragastric balloons (as compared to ORBERATM) which contain the same or a similar fill volume.
  • Figure 3 illustrates a principle or feature of an embodiment of the present invention to show an important difference between a known or standard intragastric balloon 200 (Figure 3A) and an embodiment of the present compliant intragastric balloon 300 ( Figure 3B).
  • a smaller initial shell (the left hand side of Figure 3A) is inflated (eg with a fluid such as saline) which stretches the balloon shell, thereby increasing internal pressure, and creates a rigid sphere, as shown by the right hand side of Figure 3A.
  • a compliant balloon 300 has a larger initial shell volume (the left hand side of Figure 3B) and can be inflated to a similar volume, but does not place the shell under major stretch which decreases internal pressure (as compared to the inflated Figure 3A balloon) and produces an inflated intragastric balloon with an amorphous or irregular shape, as shown by the right hand side of Figure 3B.
  • FIG. 4 Another embodiment 400 of the present invention compliant balloon (roughly kidney shaped) is shown by Figure 4, inflated within a stomach.
  • This design 400 incorporates three balloon regions: a proximal medium sized portion 410, a large central portion 420, and a smaller distal portion 430.
  • the medium proximal portion 410 provides a balloon shell surface area which contacts and exerts a pressure on the proximal stomach to thereby induce satiety.
  • the larger central portion 420 functions as a stomach space filling region which sterically reduces appetite by preventing ingested food from occupying the same stomach volume.
  • Smallest of the three compliant balloon regions, portion 430 conforms to the more muscular, narrow antrum region of the stomach helping to maintain (“anchor”) the balloon within the stoma .
  • embodiment 400 shown in Figure 4 that has a larger central sphere 420, and is overall kidney shaped.
  • the volume compliance aspect of embodiment 400, as well as it's anatomically more natural geometry provides a device that better conforms to stomach anatomy which providing maximum stomach volume occupation.
  • Figure 5 shows a dipping mandrel 500 that can used as a mold to create the balloon 400, using known silicone shell production methods.
  • the mandrel 500 has radii (shown by the arrows in Figure 5) connecting the spheres.
  • the radii can be reduced in size (shorter) to thereby making the portions 410, 420 and 430 more defined (more spherical).
  • the radii can be increased (longer) in size to thereby making the portions 410, 420 and 430 less defined (less spherical).
  • Potential benefits of better defined (reduced radii) balloon portions of the implant can include ease of implantation and the filling procedure, or compacting for delivery through the esophagus.
  • FIG. 6 shows seven (A to G) alternative compliant balloon geometries with one or more radii altered. Note the dotted transitions between the individual sections of each design, which represents the variable connecting taper/curve that could be applied between each balloon portion.
  • Proximal and distal in Figure 6 represent how the device would be placed in a patient's anatomy (proximal is closer to head).
  • Figure 7 illustrates a kidney shaped embodiment 600 shown within a human stomach.
  • Embodiment 600 has a single balloon shape (only one unity shaped balloon region). Thereby as shown in Figure 7 permitting embodiment 600 to have close conformance to internal stomach anatomy, without requiring the stomach to reshape (as would be required with a large spherical geometry intragastric balloon).
  • Embodiment 600 is also graphically illustrated in Figure 6D and 6F with a tangential shell taper.
  • Figure 8 shows features that can be added to a compliant balloon within the scope of the present invention to help maintain certain shapes, or prevent unintentional migration into the pylorus:
  • a in Figure 8 shows increased thickness on the distal balloon segment, which would increase rigidity along the section of device that is most likely to enter the pylorus;
  • B in Figure 8 shows a circumferential, or series, of rings which would prevent collapse and eventual migration of the device into the duodenum, and;
  • C in Figure 8 is one of several spines which can help maintain desired balloon shape.
  • non-spherical mandrel also can facilitate easy grasping and improved removal of completed non-spherical intragastric balloon from the mandrel because a spherical mandrel can be difficult to grasp due to the lack of grasping features on the manufactured shell of the spherical intragastric balloon.
  • An embodiment of our non-spherical intragastric balloon shell is much easier to grasp for removal from the mandrel because the shell has folds or other features in the shell that assist grasping.
  • Figure 9A to 9D show several non-spherical mandrel embodiments that incorporate features which aid removal of the shell from the mandrel.
  • the geometry of the Figure 9A to 9D mandrels is such that there exist one or more features of the resulting shell formed on the mandrel which make manipulation or grasping of the balloon much easier, as compared to a spherical intragastric balloon shell made on a spherical mandrel .
  • Figures 9A to 9D illustrate mandrel features that create a shell with a fold or fold-like geometry which result in the shell being more readily grasped and removed from the mandrel.
  • Figure 9A is a diagram of a mandrel 700 with a cavity 710 useful for making an embodiment of the present intragastric balloon.
  • Figure 9B is a diagram of another mandrel 800 useful for making another embodiment of the present intragastric balloon.
  • Mandrel 800 has one or more circular or semi-circular latitudinal ridges 810 to assist grasping and removal of the intragastric balloon formed thereon.
  • Figure 9C is a diagram of another mandrel 900 useful for making another further embodiment of the present intragastric balloon.
  • Mandrel 900 has one or more circular or semi-circular longitudinal ridges 910 to assist grasping and removal of the intragastric balloon formed thereon.
  • Figure 9D is a diagram of another mandrel 1000 useful for making another embodiment of the present intragastric balloon.
  • Mandrel 1000 has one or spaced pits 1010 to assist grasping and removal of the intragastric balloon formed thereon.
  • Figure 10 is a diagram showing an embodiment 1 100 of an inflated intragastric balloon made using mandrel 700.
  • intragastric balloons in which a radiopaque substance is incorporated into the shell of the intragastric balloon thereby dramatically improving intra-luminal visualization.
  • a suitable radiopaque substance such as barium sulfate
  • the barium sulfate is incorporated into the inner layer(s) of the intragastric device shell, while leaving the outer layers of the intragastric device shell as more resistant.
  • the Orbera intragastric device has a silicone sheath. As the Orbera balloon is inflated, the sheath stretches and tears in areas that are pre-cut. Full inflation of the balloon ensures complete deployment of the Orbera balloon and valve from its sheath. With the present compliant intragastric balloon, this same sheath is unsuitable, because the present intragastric balloon is underinflated (relative to mandrel size) so that present intragastric balloon never exerts enough force on the sheath to allow for full deployment. Therefore an alternative intragastric device delivery (insertion) method was developed as set forth below
  • one such method developed involves wrapping the intragastric balloon in a sheath 1200 with a suture that is tied in a series of slip knots 1210.
  • a slip string 1220 runs along the length of the fill tube and is long enough to pull from outside the body (after the intragastric balloon is placed in the stomach). Pulling on the string 1220 unties all of the knots 1210 and frees the (uninflated) intragastric balloon in the stomach. The string 1220 is then retrieved from the stomach and the intragastric balloon is filled as usual.
  • This sheeting can be held closed with a string or some other component that can be activated upon command. Activation of this component (string for example) would loosen the wrap and free the device. The string and wrap could then be retrieved from the stomach.
  • the compliant balloon provides: a soft, compliant implant that is capable of conforming to patient's anatomy while providing gastric volume occupation (i.e. resulting in the patient experience a feeling of fullness); greater patient tolerance of the implant, resulting in reduced recorded post-operative adverse events; low level of strain on the compliant balloons thereby increasing device longevity in the stomach and increased implant durability and resistance to degradation in the gastric environment; reduced patient ulcers and lesions that can be associated with known rigid volume occupying intragastric balloon implants; a low pressure device, as opposed to known intragastric balloons that have increased internal pressure proportional to their fill volume.
  • gastric volume occupation i.e. resulting in the patient experience a feeling of fullness
  • greater patient tolerance of the implant resulting in reduced recorded post-operative adverse events
  • low level of strain on the compliant balloons thereby increasing device longevity in the stomach and increased implant durability and resistance to degradation in the gastric environment
  • reduced patient ulcers and lesions that can be associated with known rigid volume occupying intragastric balloon implants
  • Example 1 Implantation of a Compliant Balloon
  • the compliant balloon can be made of a silicone material such as 3206 silicone. Any fill valve can be made from 4850 silicone with 6% BaSo 4 . Tubular structures or other flexible conduits can be made from silicone rubber as defined by the Food and Drug Administration (FDA) in the Code of Federal Regulations (CFR) Title 21 Section 177.2600.
  • FDA Food and Drug Administration
  • CFR Code of Federal Regulations
  • the compliant balloon is intended to occupy a gastric space while also applying intermittent pressure to various and changing areas of the stomach; the device can stimulate feelings of satiety, thereby functioning as a treatment for obesity.
  • the device is implanted transorally via endoscope into the corpus of the stomach using endoscopy. Nasal/Respiratory administration of oxygen and isoflurane is used to maintain anesthesia as necessary.
  • the compliant balloon within the scope of the present invention can be used for the treatment of obesity as follows.
  • a 45 male patient with a body mass index of 42 who has failed a regime of dieting and exercise, is recalcitrant to oral medication, declines sleeve gastrectomy, or other restrictive Gl surgery, has comorbidies including diabetes, high blood pressure and reduced life expectancy sign an informed consent for implantation of the compliant balloon.
  • midazolam conscious sedation max, 5 mg
  • endoscopy is performed to rule out any Gl abnormalities that would preclude the procedure on the patient.
  • a balloon 400 or 600 is then inserted into the gastric fundus, and 300 ml saline solution is used for balloon inflation, under direct endoscopic vision.
  • the patient remains for 2 hours in the recovery room, to verify full recovery from sedation, before discharge. Weight loss commence almost immediately and the patient reports no nausea, intolerance, abdominal pain, vomiting, or reflux, and no gastric perforation occurs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Nursing (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Surgical Instruments (AREA)

Abstract

L'invention concerne un ballon intragastrique implanté par voie trans-orale servant à traiter l'obésité et à réguler le poids incluant un ballon à taille variable doté d'une ou plusieurs régions communicantes agissant pour exercer une pression sur l'estomac, afin de conférer un effet d'occupation du volume de l'estomac, et/ou afin d'ancrer le ballon à l'intérieur de l'estomac.
PCT/US2013/063276 2010-10-18 2013-10-03 Ballon intra-gastrique servant à traiter l'obésité WO2014055766A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/433,752 US9795498B2 (en) 2010-10-18 2013-10-03 Intragastric balloon for treating obesity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/645,026 2012-10-04
US13/645,026 US8870966B2 (en) 2010-10-18 2012-10-04 Intragastric balloon for treating obesity

Publications (1)

Publication Number Publication Date
WO2014055766A1 true WO2014055766A1 (fr) 2014-04-10

Family

ID=49328689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/063276 WO2014055766A1 (fr) 2010-10-18 2013-10-03 Ballon intra-gastrique servant à traiter l'obésité

Country Status (1)

Country Link
WO (1) WO2014055766A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9445930B2 (en) 2004-11-19 2016-09-20 Fulfillium, Inc. Methods, devices, and systems for obesity treatment
US9456915B2 (en) 2004-11-19 2016-10-04 Fulfilium, Inc. Methods, devices, and systems for obesity treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084061A (en) 1987-09-25 1992-01-28 Gau Fred C Intragastric balloon with improved valve locating means
US20120095385A1 (en) * 2010-10-18 2012-04-19 Allergan, Inc. Intragastric implants with duodenal anchors
WO2012054410A2 (fr) * 2010-10-19 2012-04-26 Allergan, Inc. Implants intragastriques comprenant plusieurs chambres à fluide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084061A (en) 1987-09-25 1992-01-28 Gau Fred C Intragastric balloon with improved valve locating means
US20120095385A1 (en) * 2010-10-18 2012-04-19 Allergan, Inc. Intragastric implants with duodenal anchors
WO2012054410A2 (fr) * 2010-10-19 2012-04-26 Allergan, Inc. Implants intragastriques comprenant plusieurs chambres à fluide

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9445930B2 (en) 2004-11-19 2016-09-20 Fulfillium, Inc. Methods, devices, and systems for obesity treatment
US9456915B2 (en) 2004-11-19 2016-10-04 Fulfilium, Inc. Methods, devices, and systems for obesity treatment
US9808367B2 (en) 2004-11-19 2017-11-07 Fulfillium, Inc. Methods, devices, and systems for obesity treatment
US10179060B2 (en) 2004-11-19 2019-01-15 Fulfillium, Inc. Methods, devices, and systems for obesity treatment
US10285835B2 (en) 2004-11-19 2019-05-14 Fulfillium, Inc. Methods, devices, and systems for obesity treatment
US10524946B2 (en) 2004-11-19 2020-01-07 Fulfillium, Inc. Methods, devices, and systems for obesity treatment
US11026825B2 (en) 2004-11-19 2021-06-08 Fulfillium, Inc. Methods, devices, and systems for obesity treatment

Similar Documents

Publication Publication Date Title
US9795498B2 (en) Intragastric balloon for treating obesity
US9539133B2 (en) Stomach-spanning gastric implants
EP2629713B1 (fr) Implants gastriques s'étirant dans l'estomac
US9668901B2 (en) Intragastric implants with duodenal anchors
US8864840B2 (en) Intragastric implants with collapsible frames
US9895246B2 (en) Reactive intragastric implant devices
EP2629712B1 (fr) Implants intragastriques remplisseurs d'espace à écoulement de fluide
EP2629717B1 (fr) Implants gastriques pour la partie supérieure de l'estomac
US20140025100A1 (en) Re-shaping intragastric implants
WO2014055766A1 (fr) Ballon intra-gastrique servant à traiter l'obésité

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13774924

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14433752

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13774924

Country of ref document: EP

Kind code of ref document: A1